{Reference Type}: Journal Article
{Title}: Delta-6 desaturase FADS2 is a tumor-promoting factor in cholangiocarcinoma.
{Author}: Hasegawa K;Fujimori H;Nakatani K;Takahashi M;Izumi Y;Bamba T;Nakamura-Shima M;Shibuya-Takahashi R;Mochizuki M;Wakui Y;Abue M;Iwai W;Fukushi D;Satoh K;Yamaguchi K;Shindo N;Yasuda J;Asano N;Imai T;Asada Y;Katori Y;Tamai K;
{Journal}: Cancer Sci
{Volume}: 0
{Issue}: 0
{Year}: 2024 Aug 7
{Factor}: 6.518
{DOI}: 10.1111/cas.16306
{Abstract}: Cholangiocarcinoma is a fatal disease with limited therapeutic options. We screened genes required for cholangiocarcinoma tumorigenicity and identified FADS2, a delta-6 desaturase. FADS2 depletion reduced in vivo tumorigenicity and cell proliferation. In clinical samples, FADS2 was expressed in cancer cells but not in stromal cells. FADS2 inhibition also reduced the migration and sphere-forming ability of cells and increased apoptotic cell death and ferroptosis markers. Lipidome assay revealed that triglyceride and cholesterol ester levels were decreased in FADS2-knockdown cells. The oxygen consumption ratio was also decreased in FADS2-depleted cells. These data indicate that FADS2 depletion causes a reduction in lipid levels, resulting in decrease of energy production and attenuation of cancer cell malignancy.